Department of Health and Social Care

The National Cancer Plan, to be published in the coming weeks, will set out in more detail how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology. The National Cancer Plan will have patients at its heart and will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care, as well as prevention, and research and innovation. It will seek to improve every aspect of cancer care to better the experience and outcomes for people with cancer, including improving access to lifesaving and cutting-edge new treatment.

Research is crucial in tackling cancer, which is why the Government invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority. For example, the NIHR supported the development of an immunotherapy for patients with an aggressive form of leukaemia, which was approved for routine use in the National Health Service by the National Institute for Health and Care Excellence in November 2025.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.

NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.

NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing guidance and quality standards on the treatment and care of diabetes in England. The NICE guideline NG18, for type 1 and 2 diabetes, provides clinical guidelines for the diagnosis, treatment, and care of children and young people. Children with suspected type 1 diabetes should receive a blood test that checks blood glucose, or sugar, levels.

NG18 recommends that children and young people with suspected type 1 diabetes are referred immediately, on the same day, to a multidisciplinary paediatric diabetes team with the competencies needed to confirm diagnosis and provide immediate care.

NHS England has published the RightCare toolkit which supports good quality diabetes care for children and young adults and includes guidance on timely and accurate diagnosis.

The Government is committed to tackling preventable ill health, such as type 2 diabetes, head-on and at the earliest opportunity. Excess weight and obesity are key risk factors for type 2 diabetes and we are taking decisive action on the obesity crisis, easing the strain on the National Health Service and creating the healthiest generation of children ever.

We have delivered on our commitment to restrict junk food advertising on television and online and are delivering a ban on the sale of high-caffeine energy drinks to under 16 year olds. We are limiting volume price promotions such as “buy one get one free” on less healthy food and drink and have put in place a nationally standardised Behavioural Support for Obesity Prescribing service to ensure weight loss medicines are delivered safely and effectively. We will also double the number of patients able to access the NHS Digital Weight Management programme.

In addition, we continue to support the Healthier You NHS Diabetes Prevention Programme (NHS DPP), which has offered support to over 2.4 million people who are at risk of type 2 diabetes since its establishment in 2016. The NHS DPP is highly effective and has been found to reduce attendee’s risk of developing type 2 diabetes by 37% compared to those who did not attend.

We continue to deliver the NHS Health Check, a core component of England’s cardiovascular disease prevention programme, which aims to detect those at risk of heart disease, stroke, type 2 diabetes, and kidney disease aged between 40 and 74 years old.

As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever.

As part of this, we are committed to updating the standards which underpin the advertising restrictions on television and online and the promotion restrictions in stores and their equivalent places online on ‘less healthy’ food and drink products. The Nutrient Profiling Model (NPM) 2004/05 is plainly out of date and updating the standards will strengthen the restrictions by reflecting the latest dietary advice and more effectively target the products of most concern to childhood obesity.

The Government has met with a range of stakeholders over the past year to listen to their concerns, and officials met with Dairy UK in August 2025.

The Government remains committed to engaging relevant stakeholders and we will consult this year on the application of an updated NPM’s to the advertising and promotion restrictions to ensure they can feed in their views.

Local authorities are responsible for assessing local need for drug prevention, treatment, and recovery in their areas and for commissioning services to best meet local need. This includes work to reduce drug-related deaths.

The Department has recently launched the Drug and alcohol-related deaths dashboard, which provides information on the levels of drug and alcohol related mortality and harms, and the evidence-based interventions that local authorities and treatment providers can provide to have a positive impact on reducing deaths. Local authorities have access to this dashboard and can use it to assess need and plan interventions including in areas with higher rates of deaths. We are also improving surveillance of emerging harms and drug use patterns, with quarterly surveillance data now published to support local police and health responses to synthetic opioids.

In response to increasing drug related deaths, in 2024 the Department amended the Human Medicines Regulations 2012 to expand access to naloxone. The legislation enabled more services and professionals to supply this medication. The Department has recently launched a 10-week United Kingdom-wide public consultation on further legislative options to expand access to take-home and emergency use naloxone.

In response to the sharp rise in deaths involving cocaine, 800 deaths in 2022 to 1,195 deaths in 2024, the Department is investing an additional £200,000 in 2025/26 to develop and trial new brief interventions to target the rise in cocaine and alcohol-related cardiovascular deaths, particularly among men. The pilots will be run in acute hospital alcohol care teams with a view to making them available for use nationally across all healthcare settings in the next financial year.

Through the Government's Addiction Healthcare Goals Reducing Drug Deaths Innovation Challenge, twelve projects have received UK and Scottish government funding to develop and test innovative drug overdose detection, response, and rescue technologies and medicines with relevant populations. Future funding and support through the Addiction Healthcare Goals programme are being explored to further enable the advanced development and UK roll-out of novel drug and alcohol addiction technologies to improve healthcare and prevent harms and deaths.

Children’s early years are crucial to their development, health, and life chances. Prioritising quality support during the critical 1,001 days offers a real opportunity to improve outcomes, reduce health disparities, and deliver on our ambition to raise the healthiest generation of children.

From April 2026, Best Start Family Hubs will expand to every single local authority, backed by over £500 million to reach up to half a million more children. This funding will enable integration of health services in Best Start Family Hubs across all local authorities and is fundamental to improving outcomes for babies, children, and their families and for delivering on neighbourhood health.

The Department has commissioned an independent evaluation to help us understand the effectiveness and impact of Start for Life, now Healthy Babies, services. The final report, expected in 2026, will identify comparison groups where appropriate and will be integral to making evidence-based decisions for improving outcomes for babies and children.

The Adult Substance Misuse Treatment Statistics 2024 to 2025 report and the Children’s Substance Misuse Treatment Statistics 2024 to 2025 report, both published in December 2025, show that in England between April 2024 and March 2025 there were 37,117 people under the age of 25 years old receiving drug and alcohol treatment in the community.

The General Dental Council (GDC) regulates United Kingdom dentistry and sets the standards for all applicants to its registers. Routes to registration for overseas qualified dentists are set out in legislation.

The Government is working with the GDC to increase the number of overseas-qualified dentists gaining registration to help address National Health Service workforce shortages.

The GDC already offers priority booking to refugee dentists on its Overseas Registration Exam (ORE). Last year I asked the GDC to develop a plan to urgently cut the high ORE waiting list and in November received an update on their work. I have been assured that significant improvements to international registration are expected this year.

I have also asked the GDC for an improved ORE booking system for the new ORE delivery contract, coming into effect from April 2026, and to explore prioritisation of UK resident candidates. I will meet the GDC again for an update on this work once the new contract is finalised.

Improving elective performance and cutting waiting lists is a priority for the Government. We have made significant progress with patients being seen faster, and November saw the second biggest drop in the waiting list for 15 years outside of the early days of the pandemic.

Fit for the Future: The 10-Year Health Plan for England and the Partnership Agreement between NHS England and the Independent Healthcare Providers Network reaffirmed our continued commitment to using independent sector capacity to improve access, reduce backlogs, and build a sustainable healthcare system.

Between April 2025 and November 2025, the latest month for which data is available, independent sector providers delivered 9.9% of all elective ordinary and day case procedures for the National Health Service.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

The NHS Learning Disability Improvement Standards support National Health Service trusts to assess the quality of care provided for people with a learning disability and were designed with lived experience at the centre of the process. The standards and easy read information are available on the NHS England website.

To understand how well organisations are meeting the standards, the NHS Benchmarking Network undertakes an annual data collection exercise, with further information avaiable at the NHS Benchmarking Network website. All annual summary reports are published on the Learning Disability Improvement Standards Hub website. Each trust that participates in the exercise also receives their own bespoke report and are encouraged to share learning at the local level in suitable formats for the populations they serve.

Ahead of each annual benchmarking exercise, people with a learning disability and user-led organisations are engaged to design and revise the metrics which are asked of NHS organisations. This process recognises that people with lived experience are best placed to ask questions concerning the quality of services they expect and has recently been facilitated by Learning Disability England. Input is also sought from clinicians, managers, and senior leadership, ensuring greater transparency and accountability.

To accelerate progress towards the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease Modern Service Framework (CVD MSF) in 2026. The CVD MSF will support consistent, high quality, and equitable care whilst fostering innovation across the cardiovascular disease pathway.

The Department and NHS England are engaging widely throughout the development of the CVD MSF to ensure that we prioritise ambitious, evidence-led, and clinically informed approaches to prevention, treatment, and care, and as part of this we are considering the role of levers and incentives.

Of the 17 executive senior managers at NHS England who have left since 1 March 2025 and received a payment either in lieu of notice or in lieu of annual leave, six have since been re-employed in the National Health Service, an NHS body, an arm’s length body (ALB), or a Government department. We do not hold information related to consultancy.

One of these six individuals received a redundancy payment which is in the scope of the clawback provisions. Recovery has commenced for a partial recovery proportionate to their gap in NHS employment.

For the other five people securing re-employment in the NHS, an NHS body, an ALB, or a Government department, their payments in lieu related to annual leave or notice, and therefore were not within the scope of clawback arrangements.

Whilst recovery action has actively commenced for the individual in the scope of the claw back provisions, no funds have been recovered to date.

NHS England has engaged with providers and commissioners as part of the development of the currency models and guide prices for autism assessment services and certain attention deficit hyperactivity disorder (ADHD) services prior to their inclusion within the NHS Payment Scheme.

The statutory consultation for the NHS Payment Scheme 2026/27, which closed on 16 December 2025, provided an opportunity for all service providers to review the consultation guidance and provide comments and feedback, with further information avaiable on the NHS.UK website. NHS England is currently reviewing this feedback to inform the final 2026/27 Payment Scheme. The NHS England Payment Team invited all known ADHD and autism service providers to a pre-consultation webinar which set out the overall changes to the payment scheme. NHS England will continue to engage service providers as part of the next phase of development following the publication of the NHS Payment Scheme 2026/27.

As set out in the NHS Payment Scheme consultation, we have used a range of existing local prices agreed between commissioners and providers as the basis for the guide prices in the consultation. The payment scheme consultation provides the opportunity for providers to comment on the proposed guide prices, and we will consider all the responses received before finalising the payment scheme for 2026/27. These proposals for 2026/27 represent the first stage of planning pricing development for autism assessment services and certain ADHD services.

NHS England has set out what is included within assessments for ADHD and autism within a supporting document to the NHS Payment Scheme 2026/27 statutory consultation. This guidance also links to clinical guidance from the National Institute for Health and Care Excellence and other guidance which may support the commissioning and provision of these services. Guidance setting out the all age autism assessment pathway intended to help integrated care boards deliver improved outcomes in all age autism assessment pathways was written by NHS England in April 2024 and is available on the NHS.UK website.

NHS England has engaged with providers and commissioners as part of the development of the currency models and guide prices for autism assessment services and certain attention deficit hyperactivity disorder (ADHD) services prior to their inclusion within the NHS Payment Scheme.

The statutory consultation for the NHS Payment Scheme 2026/27, which closed on 16 December 2025, provided an opportunity for all service providers to review the consultation guidance and provide comments and feedback, with further information avaiable on the NHS.UK website. NHS England is currently reviewing this feedback to inform the final 2026/27 Payment Scheme. The NHS England Payment Team invited all known ADHD and autism service providers to a pre-consultation webinar which set out the overall changes to the payment scheme. NHS England will continue to engage service providers as part of the next phase of development following the publication of the NHS Payment Scheme 2026/27.

As set out in the NHS Payment Scheme consultation, we have used a range of existing local prices agreed between commissioners and providers as the basis for the guide prices in the consultation. The payment scheme consultation provides the opportunity for providers to comment on the proposed guide prices, and we will consider all the responses received before finalising the payment scheme for 2026/27. These proposals for 2026/27 represent the first stage of planning pricing development for autism assessment services and certain ADHD services.

NHS England has set out what is included within assessments for ADHD and autism within a supporting document to the NHS Payment Scheme 2026/27 statutory consultation. This guidance also links to clinical guidance from the National Institute for Health and Care Excellence and other guidance which may support the commissioning and provision of these services. Guidance setting out the all age autism assessment pathway intended to help integrated care boards deliver improved outcomes in all age autism assessment pathways was written by NHS England in April 2024 and is available on the NHS.UK website.

NHS England has engaged with providers and commissioners as part of the development of the currency models and guide prices for autism assessment services and certain attention deficit hyperactivity disorder (ADHD) services prior to their inclusion within the NHS Payment Scheme.

The statutory consultation for the NHS Payment Scheme 2026/27, which closed on 16 December 2025, provided an opportunity for all service providers to review the consultation guidance and provide comments and feedback, with further information avaiable on the NHS.UK website. NHS England is currently reviewing this feedback to inform the final 2026/27 Payment Scheme. The NHS England Payment Team invited all known ADHD and autism service providers to a pre-consultation webinar which set out the overall changes to the payment scheme. NHS England will continue to engage service providers as part of the next phase of development following the publication of the NHS Payment Scheme 2026/27.

As set out in the NHS Payment Scheme consultation, we have used a range of existing local prices agreed between commissioners and providers as the basis for the guide prices in the consultation. The payment scheme consultation provides the opportunity for providers to comment on the proposed guide prices, and we will consider all the responses received before finalising the payment scheme for 2026/27. These proposals for 2026/27 represent the first stage of planning pricing development for autism assessment services and certain ADHD services.

NHS England has set out what is included within assessments for ADHD and autism within a supporting document to the NHS Payment Scheme 2026/27 statutory consultation. This guidance also links to clinical guidance from the National Institute for Health and Care Excellence and other guidance which may support the commissioning and provision of these services. Guidance setting out the all age autism assessment pathway intended to help integrated care boards deliver improved outcomes in all age autism assessment pathways was written by NHS England in April 2024 and is available on the NHS.UK website.

The 10-Year Health Plan was published on 3 July 2025, which sets out how the Government will ensure the National Health Service is fit for the future, where artificial intelligence (AI) will play a fundamental role in this transformation. As part of the 10-Year Health Plan, the Government is supporting the use of AI-enabled appointment and scheduling tools to reduce the administrative burden on clinicians, with early trials showing an increase in productivity and clinician time saved.

An accident and emergency demand forecasting tool is now available to all NHS trusts and is already in use by 50 NHS organisations, helping them plan how many people are likely to need emergency care and treatment on any given day. While this tool does not schedule appointments specifically, it uses AI to predict emergency care demand, enabling trusts to plan staffing and resources more effectively and reduce pressure on services.

The NHS continues to fund both pilots and scaling of different software products that enable the use of AI in scheduling and managing secondary care appointments. Typically, these include the ability to predict Did Not Attends, to reschedule appointments at short notice, and improve utilisation of clinician time.

Work has begun to deliver the NHS’s Medium Term Planning Framework commitment that, from April 2026, the NHS will begin to move to a unified access model, using AI-assisted triage. This model should effectively guide patients to self-care or to the appropriate care setting, through a single user interface delivered via the NHS App but with an integrated telephony and in-person offering.

Further to this, features set to be developed through the NHS App will include the ability to book and manage remote or face-to-face appointments, receive personalised health advice, see when vaccines are up-to-date, and book appointments to get them organised, and find travel vaccine info.

Additionally, DrDoctor, an AI tool, had a three-year contract from 2021 to 2024 with the NHS AI Lab Award. It supports hospitals by providing AI guidance on overbooking as a more efficient and economical solution to increase NHS appointment capacity. This has been shown to free up clinician and administrative time, improve patient care and experience, and predict which patients are at the highest risk of missing an appointment with “Did Not Attend” DNA Prediction.

No commissioners have been appointed. Baroness Louise Casey of Blackstock chairs the Independent Commission into adult social care, alongside a dedicated secretariat team.

Baroness Casey and the Commission’s secretariat are based in the Cabinet Office. The secretariat has a total of ten officials, eight are employed by the Department of Health and Social Care, and two by the Cabinet Office. One external individual has been hired as contingent labour to support the work of the Commission’s secretariat. There are a further four officials working in the Commission’s sponsorship function based in the Department of Health and Social Care.

As the Commission is independent, the secretariat may expand as it carries out its work and as Baroness Casey considers what further skills and expertise she needs.

For 2025/26, the Department of Health and Social Care indicatively made available £2.9 million to support the Commission’s work and continue to keep the budget under review. As the Commission is independent, they will be responsible for reporting on their financial expenditure.

The independence of the Commission means the Department of Health and Social Care does not track the number of meetings the Commission has held. Engagement decisions are for Baroness Casey and her team to decide. The Commission has set out that it has met with over 350 people including those drawing on care and supporting, national organisations and delivery or provider organisations.

Details about how to engage with the Commission, including via the portal, are available on its website in an online-only format.

No commissioners have been appointed. Baroness Louise Casey of Blackstock chairs the Independent Commission into adult social care, alongside a dedicated secretariat team.

Baroness Casey and the Commission’s secretariat are based in the Cabinet Office. The secretariat has a total of ten officials, eight are employed by the Department of Health and Social Care, and two by the Cabinet Office. One external individual has been hired as contingent labour to support the work of the Commission’s secretariat. There are a further four officials working in the Commission’s sponsorship function based in the Department of Health and Social Care.

As the Commission is independent, the secretariat may expand as it carries out its work and as Baroness Casey considers what further skills and expertise she needs.

For 2025/26, the Department of Health and Social Care indicatively made available £2.9 million to support the Commission’s work and continue to keep the budget under review. As the Commission is independent, they will be responsible for reporting on their financial expenditure.

The independence of the Commission means the Department of Health and Social Care does not track the number of meetings the Commission has held. Engagement decisions are for Baroness Casey and her team to decide. The Commission has set out that it has met with over 350 people including those drawing on care and supporting, national organisations and delivery or provider organisations.

Details about how to engage with the Commission, including via the portal, are available on its website in an online-only format.

No commissioners have been appointed. Baroness Louise Casey of Blackstock chairs the Independent Commission into adult social care, alongside a dedicated secretariat team.

Baroness Casey and the Commission’s secretariat are based in the Cabinet Office. The secretariat has a total of ten officials, eight are employed by the Department of Health and Social Care, and two by the Cabinet Office. One external individual has been hired as contingent labour to support the work of the Commission’s secretariat. There are a further four officials working in the Commission’s sponsorship function based in the Department of Health and Social Care.

As the Commission is independent, the secretariat may expand as it carries out its work and as Baroness Casey considers what further skills and expertise she needs.

For 2025/26, the Department of Health and Social Care indicatively made available £2.9 million to support the Commission’s work and continue to keep the budget under review. As the Commission is independent, they will be responsible for reporting on their financial expenditure.

The independence of the Commission means the Department of Health and Social Care does not track the number of meetings the Commission has held. Engagement decisions are for Baroness Casey and her team to decide. The Commission has set out that it has met with over 350 people including those drawing on care and supporting, national organisations and delivery or provider organisations.

Details about how to engage with the Commission, including via the portal, are available on its website in an online-only format.

No commissioners have been appointed. Baroness Louise Casey of Blackstock chairs the Independent Commission into adult social care, alongside a dedicated secretariat team.

Baroness Casey and the Commission’s secretariat are based in the Cabinet Office. The secretariat has a total of ten officials, eight are employed by the Department of Health and Social Care, and two by the Cabinet Office. One external individual has been hired as contingent labour to support the work of the Commission’s secretariat. There are a further four officials working in the Commission’s sponsorship function based in the Department of Health and Social Care.

As the Commission is independent, the secretariat may expand as it carries out its work and as Baroness Casey considers what further skills and expertise she needs.

For 2025/26, the Department of Health and Social Care indicatively made available £2.9 million to support the Commission’s work and continue to keep the budget under review. As the Commission is independent, they will be responsible for reporting on their financial expenditure.

The independence of the Commission means the Department of Health and Social Care does not track the number of meetings the Commission has held. Engagement decisions are for Baroness Casey and her team to decide. The Commission has set out that it has met with over 350 people including those drawing on care and supporting, national organisations and delivery or provider organisations.

Details about how to engage with the Commission, including via the portal, are available on its website in an online-only format.

The Government is developing a Palliative Care and End of Life Care Modern Service Framework for England. I refer the Noble Lord to the Written Ministerial Statement HLWS1086 I gave to the House on 24 November 2025.

The membership of the National Maternity and Neonatal Taskforce is currently being finalised, and the first meeting of the taskforce will be held early this year. Following engagement with some families and stakeholders, the Terms of Reference are also being developed and will be published in due course.

This will allow the taskforce to begin to address some of the entrenched issues we know exist and be fully prepared to act once the national maternity and neonatal investigation reports in Spring 2026.The taskforce will work rapidly to transform the investigation’s recommendations into a deliverable new national action plan to drive real change.

The membership of the National Maternity and Neonatal Taskforce is currently being finalised, and the first meeting of the taskforce will be held early this year. Following engagement with some families and stakeholders, the Terms of Reference are also being developed and will be published in due course.

This will allow the taskforce to begin to address some of the entrenched issues we know exist and be fully prepared to act once the national maternity and neonatal investigation reports in Spring 2026.The taskforce will work rapidly to transform the investigation’s recommendations into a deliverable new national action plan to drive real change.

The sickness to prevention shift is one of three major shifts described in the 10-Year Health Plan to transform the health service. As part of this shift, prevention accelerators will demonstrate that investment in high-impact interventions on cardiovascular disease and diabetes can improve population health and reduce demand for National Health Services, such as elective appointments and general practice appointments.

Work to agree the formal arrangements with prevention accelerators is ongoing, alongside finalising the specific high-impact interventions that they will prioritise. We will share further information on the action underway in due course.

The Government is unable to comment or provide details on the personal health information of named individuals.

NHS England commissions health services in prisons, and healthcare providers monitor the health of all individuals in custody to ensure they receive appropriate care.

The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR) and in 2024/25 spent £141.6 million on cancer research, signalling its high priority.

One example of a recent investment into rare cancers is the NIHR’s investment of £13.7 million in December 2025 to support ground-breaking research to develop novel brain tumour treatments in the United Kingdom, with significant further funding announcements expected shortly. Research specifically on Ocular Melanoma includes a study completed in 2022 to develop AI Techniques to Predict Eye Cancer Using Big Longitudinal Data. The NIHR is committed to ensuring that all patients, including those with rare cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments, by working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including for rare cancers

The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on rare cancers to take place in England, by ensuring the patient population can be more easily contacted by researchers

The NIHR continues to welcome funding applications for research into less common cancers, including ocular cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

The Department has no plans to ask the National Institute for Health and Care Excellence (NICE) to conduct a review of the NICE guideline on the treatment and management of depression, reference code NG222.

NICE is an independent body and is responsible for taking decisions on whether its guidelines should be updated in light of new evidence and changes in clinical practice. NICE operates an active surveillance programme and when new evidence emerges, it proactively considers whether existing guidance should be reviewed and, if appropriate, updated. Decisions as to whether NICE will create new, or update existing, guidance are overseen by an integrated, cross-organisational prioritisation board. NICE has no current plans to review intravenous racemic ketamine in the context of the depression guideline.

The Medicines and Healthcare products Regulatory Agency (MHRA) has updated its safety advice on mefloquine to reflect the risk of neuropsychiatric side effects, advising that it should not be used for chemoprophylaxis in individuals with a history of psychiatric disturbance.

National Institute for Health and Care Excellence guidance states that mefloquine should not be prescribed to people with current or past psychiatric disorders, suicidal ideation or behaviour, or with epilepsy or any form of convulsion.

The clinical management of suspected mefloquine intoxication has recently been reviewed with the NHS England Armed Forces Clinical Reference Group. This review advised that clinicians should assess patients individually and are expected to take a full drug and alcohol history, including any previous mefloquine use.

NHS England is considering adding screening for prior mefloquine use and any associated adverse events to initial Op COURAGE and Op RESTORE assessments. Additional clinical guidance on mefloquine and its potential adverse effects is being developed and through the Five Eyes partnership discussions are being arranged with the United States to support continuous learning and best practice in the management of suspected mefloquine intoxication.

Final approval for the business case for the rebuild of Weybridge Health Centre was granted by NHS England on 4 November 2025. Planning approvals have been secured, and pre-construction demolition began on 10 November 2025. Full construction is scheduled to start in late January 2026.

Final approval for the business case for the rebuild of Weybridge Health Centre was granted by NHS England on 4 November 2025. Planning approvals have been secured, and pre-construction demolition began on 10 November 2025. Full construction is scheduled to start in late January 2026.

The Department is currently developing the National Cancer Plan for England, which will be published shortly. The plan will build on the commitment in the 10-Year Health Plan to provide comprehensive molecular profiling of all cancers. Genomic testing is a key element of molecular profiling.

We also recognise the important role that nongenomic biomarkers play in identifying the most effective treatments for individual patients. The plan will consider how to ensure access to high-quality treatment, including access to testing that determines eligibility for precision testing.

Funding for pharmaceutical services is through the Community Pharmacy Contractual Framework (CPCF) settlement. For 2025/26, this was increased to £3.073 billion, of which £900 million is the amount pharmacy contractors are allowed to retain as medicine margin, the difference between the reimbursement price and the purchase price paid by the pharmacy contractor.

The Department, along with Community Pharmacy England, the representative body of community pharmacies, assesses the medicines margin retained by community pharmacies in totality, through a ‘quarterly margin survey’. If too much medicine margin is being delivered, then downwards adjustments, or clawbacks, are made to bring this in line with the allowed medicine margin as agreed under the CPCF settlement.

The economic analysis is considered as part of the wider decision on the CPCF settlement, which was agreed with Community Pharmacy England, the representative body of community pharmacies. The medicine margin adjustment made each quarter, including the downward adjustment of £16.8 million per quarter made in January 2026, is operating within the agreed 2025/26 CPCF settlement.

Advice provided by the UK Health Security Agency to the Government, which includes the Department, on the health impacts of electromagnetic fields associated with telecommunications masts is publicly available on the GOV.UK website, at the following link:

https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health

The Soft Drinks Industry Levy (SDIL) and National Insurance contributions are the responsibility of HM Treasury and packaging taxes fall under the remit of the Department for Environment, Food, and Rural Affairs.

The Nutrient Profile Model (NPM) is under the remit of the Department of Health and Social Care. We are committed to updating the standards which underpin the advertising restrictions on television and online and the promotion restrictions in stores and their equivalent places online on ‘less healthy’ food and drink products. The NPM 2004/05 is plainly out of date and updating the standards will strengthen the restrictions by reflecting the latest dietary advice and more effectively target the products of most concern to childhood obesity. An impact assessment will be published alongside a consultation later this year.

It was announced at Budget 2025 that milk based and milk substitute drinks, for instance soya, almond, and/or oat, would be included in the scope of the SDIL from 1 January 2028. These reforms are not expected to have any significant macroeconomic impacts, including on employment, on the basis that the levy is limited to soft drinks, and an estimated 11% of United Kingdom soft drink sales will be affected. A full assessment of the impacts of these changes is included within the Strengthening the Soft Drinks Industry Levy – Summary of Responses document. This is available at the following link:

https://www.gov.uk/government/consultations/strengthening-the-soft-drinks-industry-levy/outcome/strengthening-the-soft-drinks-industry-levy-summary-of-responses#assessment-of-impacts

A Tax Information and Impact Note (TIIN) was published alongside the introduction of the bill, containing the changes to employer National Insurance contributions. The TIIN sets out the impact of the policy on the exchequer, the economic impacts of the policy, and the impacts on individuals, businesses, and civil society organisations, as well as an overview of the equality impacts. The Government protected the smallest hospitality businesses from recent changes to employer National Insurance by increasing the Employment Allowance to £10,500.

The Department for Environment, Food, and Rural Affairs published the updated impact assessment of the packaging Extended Producer Responsibility scheme in October 2024, which evaluated the overall effects on packaging producers, without disaggregating by sector.

The Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR).

The NIHR is continuing to invest in brain tumour research. For example, in December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million in the consortium with significant further funding due to be awarded early in 2026. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.

Brain tumours are one of the toughest cancers to treat. This new NIHR investment will help researchers and clinicians understand the disease better, test new treatments earlier and make trials available to more adults and children closer to home.

The consortium brings together 48 organisations from across leading universities, National Health Service trusts, and charities, along with patients, to help deliver better research, faster. It is a coordinated national effort to improve the development and evaluation of treatments for brain tumours across adult and paediatric populations.

The NIHR continues to welcome high quality funding applications for research into any aspect of human health and care, including low-grade glioma and other rare brain tumours.

Data for the Gloucester constituency is not available, as workforce information is not collected at a parliamentary constituency level.

Between June 2024 and October 2025, the NHS Gloucestershire Integrated Care Board saw an increase of 128 full‑time equivalent mental health staff, rising from 1,416 to 1,544, representing 9.1% growth, compared with 5% nationally over the same period.

NHS England’s London Region Specialised Commissioning is currently undertaking a tabletop review of Tier 4 (T4) Personality Disorder inpatient provision within the London footprint. This review is being led by the Nursing and Quality and Mental Health teams and covers all units providing national T4 Personality Disorder inpatient services, which are all located in London.

The review has been initiated in response to a number of quality and environmental concerns identified within the provision and is assessing the effectiveness of the current service model, its clinical distinctiveness, equity of access, and its alignment with national policy objectives.

Significant action is underway to improve the quality and accessibility of health and care services for people with a learning disability at a local level, helping to deliver the shift from treatment to prevention, outlined in our 10-Year Health Plan, which is avaiable at the following link:

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

The national Learning Disabilities Health Check Scheme is designed to encourage general practices to identify all patients aged 14 years old and over with a learning disability, and to offer them an annual health check and health action plan. Further information on the Learning Disabilities Health Check Scheme is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/learning-disabilities-health-check-scheme

The latest published data for Surrey Heath shows that 82.78% of people with a learning disability in the area had completed a health check, and that 80.19% of learning disability patients in Surrey Heath had a completed health action plan. The latest published data for Surrey Heath is avaiable at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/learning-disabilities-health-check-scheme/england-march-2025

According to recently published data on Health and Care of People with Learning Disabilities, 81.5% of people with a learning disability had completed an annual health check in England. Further information on the recently published data on Health and Care of People with Learning Disabilities is avaiable at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/health-and-care-of-people-with-learning-disabilities/experimental-statistics-2024-to-2025

The Surrey All Ages Mental Health, Learning Disabilities and Autism Oversight Committee routinely monitors the following:

- admissions and discharges for adults, and children and young people with a learning disability and any barriers to timely discharge;

- mandatory training on learning disability and autism;

- performance on Care (Education) and Treatment Reviews and commissioner oversight visits;

- Dynamic Support Register governance; and

- implementation of the Reasonable Adjustments Digital Flag.

Significant action is underway to improve access to and the quality of care for people with a learning disability. This will help deliver the shift from treatment to prevention, outlined in our 10-Year Health Plan, with further information avaiable at the following link:

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

As part of this we are rolling out mandatory training for health and social care staff, improving identification on the general practice learning disability register and uptake of annual health checks, and implementing a Reasonable Adjustment Digital Flag in health and care records to ensure care is tailored appropriately. The NHS Learning Disability Improvement Standard also supports trusts by setting guidance on safe, personalised, and high-quality care provision. The standards  are designed to support organisations in assessing the quality of their services and to promote uniformity across the National Health Service in the care and treatment provided to people with a learning disability.  Further information on the standards is avaiable at the following link:

https://www.england.nhs.uk/learning-disabilities/about/resources/the-learning-disability-improvement-standards-for-nhs-trusts/

Each integrated care board must also have an executive lead for learning disability and autism and must demonstrate how they will reduce inequalities for people with a learning disability within their five year strategic plans under the Medium-Term Planning Framework. Further information is avaiable on the Medium-Term Planning Framework at the following link:

https://www.england.nhs.uk/long-read/medium-term-planning-framework-delivering-change-together-2026-27-to-2028-29/

Decisions on whether new medicines should be routinely funded by the National Health Service in England are made by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of their costs and benefits. NICE is currently re-evaluating brexucabtagene autoleucel (Tecartus) to determine whether it can be recommended for routine NHS use, taking into account real-world evidence generated through its use in the Cancer Drugs Fund. NICE has been unable to recommend the treatment in final draft guidance, which is available at the following link:

https://www.nice.org.uk/guidance/indevelopment/gid-ta11545/documents

This is because the available evidence does not suggest that brexucabtagene autoleucel is value for money in this population. Final guidance has not yet been published, and consultees have until 19 January to appeal NICE’s final draft recommendations.

In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.

Under the Equality Act 2010, health and care organisations have a legal duty to make changes in their approach and provision to ensure that services are as accessible to disabled people as they are for everybody else.

All National Health Service organisations and publicly funded social care providers are expected to meet the Accessible Information Standard, which details the recommended approach to supporting the information and communication support needs of people with a disability, impairment or sensory loss, including Deaf and blind people.

We welcome the British Sign Language Advisory Board’s report, Locked out: Exclusion of deaf and deafblind BSL users from health and social care in the UK. We will carefully consider its recommendations, including how, in the context of our work on the 10-Year Health Plan and reform of adult social care, we can improve the experiences of Deaf and blind people when accessing health and care services.